Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department
Detection Principle
ImmunoAssay-Antibody
Target
IgM/IgG
Testing Method Category
Testing Method
kit
Testing Method - Additional Info
VivaDiag COVID?19 IgM/IgG Rapid Test lateral flow immunoassay (LFIA)
Reported Performance
Sensitivity: 18.4%; specificity: 91.7%; NPV: 26.2%; PPV: 87.5%
Sample Size
110 subjects
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements